Obesity drug maker Sciwind targets IPO, with heavyweight backers
Supported by Tencent and Meituan, the biotech aims to launch a targeted GLP-1 drug next year that could challenge established products, but it faces stiff competition Key Takeaways: • Clinical…
FAST NEWS: Structure Therapeutics Leaps in U.S. Trading Debut
The latest: Innovative drug developer Structure Therapeutics Inc. (GPCR.US) made its IPO trading debut last Friday, becoming the first major U.S. listing by a Chinese company this year.Looking up: The company…
